What are the side effects of high‑intensity statin therapy in a 64‑year‑old man with a coronary calcium score of 1100, and does it increase the risk of dementia?

Side Effects of High-Intensity Statin Therapy and Dementia Risk

High-intensity statin therapy has small but real risks including myalgia, a modest increase in new-onset diabetes (particularly in those already at risk), and rare hepatotoxicity or rhabdomyolysis, but does NOT increase dementia risk—in fact, statins appear protective against dementia, particularly with longer duration of use.

Common and Clinically Significant Side Effects

Muscle-Related Effects

Myalgia is frequently reported by patients on statins, but placebo-controlled trials show statins do not have a major causative role in most muscle complaints 1. True statin-associated myopathy and rhabdomyolysis are rare but more likely with high-intensity therapy, especially in elderly patients with multiple comorbidities and drug interactions 2.

New-Onset Diabetes Mellitus

High-dose statins carry a small increased risk of developing diabetes, with approximately 31-34 events per 1000 person-years for atorvastatin and rosuvastatin 2. However, this risk is:

• Most apparent in patients already at risk for diabetes (metabolic syndrome, elevated fasting glucose)
• Far outweighed by cardiovascular benefits, even in diabetic populations 2
• Less common with fluvastatin and lovastatin compared to atorvastatin, rosuvastatin, and simvastatin 2

Hepatotoxicity

Severe liver enzyme elevations are uncommon with low-to-moderate dose statins 1. Routine monitoring is reasonable but severe hepatotoxicity remains rare.

Other Rare Effects

• Interstitial lung disease: Idiosyncratic and rare 2
• Cataract surgery risk: One trial (HOPE-3) found increased risk, but this was not replicated in other prevention trials 1
• Erectile dysfunction and gynecomastia: Conflicting data; statins may actually be protective against ED through improved endothelial function 2

Statins and Dementia: The Evidence is Reassuring

The most recent and comprehensive meta-analysis (2025) including over 7 million patients demonstrates that statin use significantly reduces dementia risk 3:

• All-cause dementia: HR 0.86 (95% CI: 0.82-0.91, p<0.001)
• Alzheimer's disease: HR 0.82 (95% CI: 0.74-0.90, p<0.001)
• Vascular dementia: HR 0.89 (95% CI: 0.77-1.02, p=0.093)

Key Protective Findings

• Duration matters: Statin exposure >3 years showed the greatest protection (HR 0.37,95% CI: 0.30-0.46) 3
• Rosuvastatin demonstrated the most pronounced protective effect (HR 0.72,95% CI: 0.60-0.88) 3
• Patients with type 2 diabetes showed significant dementia risk reduction (HR 0.87) 3

The 2016 USPSTF guideline confirms no clear evidence of decreased cognitive function with statin use, consistent with systematic reviews showing no effect on Alzheimer's disease or dementia incidence 1.

Clinical Application for Your 64-Year-Old Patient

Given a coronary calcium score of 1100, this patient has:

• Severe subclinical atherosclerosis indicating very high ASCVD risk equivalent to secondary prevention populations
• Clear indication for high-intensity statin therapy to reduce cardiovascular events and mortality

Risk-Benefit Balance

• Benefits: Substantial reduction in MI, stroke, and cardiovascular mortality
• Risks: Small diabetes risk (monitor glucose), rare myopathy (educate on symptoms), but no dementia risk—actually protective

Monitoring Strategy

• Baseline and periodic liver enzymes (though severe elevations are rare)
• Fasting glucose and HbA1c monitoring given diabetes risk
• Educate patient to report unexplained muscle pain, weakness, or dark urine
• Reassure regarding cognitive safety—statins do not cause dementia

Common Pitfalls to Avoid

1. Don't withhold statins due to dementia concerns—the evidence shows protection, not harm 3
2. Don't attribute all muscle complaints to statins—placebo-controlled data show most myalgia is not statin-related 1
3. Don't ignore diabetes risk in high-risk patients—monitor glucose but recognize cardiovascular benefits far exceed this small risk 2
4. Don't use age alone as a reason to avoid statins—the patient at 64 years is in the age range with proven benefit 1, 4

With a calcium score of 1100, this patient's ASCVD risk is sufficiently high that high-intensity statin therapy is clearly indicated, and concerns about dementia should not factor into the decision—if anything, the neuroprotective effects provide additional benefit 3.